用于治疗前列腺癌的雄激素受体拮抗剂  

Androgen Receptor Antagonists for the Treatment of Prostate Cancer

作　　者：王飏[1] 宋丽君[1] 王举波[1] 胡珀[1] 李志裕[1] 

机构地区：[1]中国药科大学药物化学教研室,江苏南京210009

出　　处：《药学进展》2012年第6期251-257,共7页Progress in Pharmaceutical Sciences

摘　　要：前列腺癌是男性泌尿生殖系统常见的恶性肿瘤,雄激素受体与前列腺细胞发育和前列腺癌发生密切相关,有可能成为治疗前列腺癌的重要靶点。对前列腺癌进行去势治疗后却常见发生更为凶险的去势抵抗性前列腺癌,因此,寻找对去势抵抗性前列腺癌有效的雄激素受体拮抗剂是当今研究热点。综述雄激素受体拮抗剂的作用机制及研究进展。Prostate cancer is a malignancy commonly occuring in male genitourinary system. Androgen receptor promotes gene transcription in prostate cell growth and carcinogenesis of prostate cancer, which makes it to become an important target in prostate cancer treatment possibly. Prostate cancer may be deteriorated into be castration-resistant prostate cancer easily after androgen deprivation therapy, so it is popular to seek the effective androgen receptor antagonists for treating of castration-resistant prostate cancer. This review focuses on the action mechanism and the development of androgen receptor antagonists for the treatment of prostate cancer.

关 键 词：去势抵抗性前列腺癌 雄激素受体拮抗剂 作用机制 

分 类 号：R737.25[医药卫生—肿瘤]